Embed Size (px)
Citation preview
ADVANCE PROGRAMME CALL FOR ABSTRACTS
www.idf.org/congress
TABLE OF CONTENTS
Welcome to the IDF Congress 2017 3Welcome to Abu Dhabi 4Congress committees 5Key dates 7Congress-at-a-glance 8Why attend the IDF Congress 2017? 9Programme committee 10Learning objectives 14Programme preview 16Programme topic overview 18Call for abstracts 24Registration 28Accommodation 30Travel and visa 34Contact 36IDF 2017: a healthy congress 37
International Diabetes Federation
The International Diabetes Federation (IDF) is an umbrella organisation of over 230 national diabetes associations in 170 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950.
IDF is a diverse and inclusive multi-cultural network of national diabetes associations and an authoritative global voice in non-communicable diseases.
The Federation’s activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization (WHO) and the Pan American Health Organization (PAHO). For more information please visit www.idf.org
IDF | Promoting diabetes care, prevention and a cure worldwide Please note, information in the the Advance Programme is subject to change.
1
It gives me great pleasure to invite you to attend the IDF Congress 2017 in Abu Dhabi, United Arab Emirates.
The 2017 congress marks a welcome return to the United Arab Emirates following the very successful edition held in Dubai in 2011. Diabetes continues to have a significant impact in the Middle East and North Africa region with one in ten adults living with diabetes in 2015. Over the past three decades progressive urbanisation, increased life expectancy and economic development associated with a shift to unhealthy lifestyles have resulted in a huge explosion in type 2 diabetes. The UAE is particularly affected with one in five people currently living with diabetes.
With the number of people with diabetes in the region expected to more than double within the next twenty years, Abu Dhabi is the perfect location to bring together the extensive global network of physicians, scientists, nurses, educators, other healthcare professionals, government officials, policy makers and diabetes associations that IDF represents. The IDF Congress will continue to provide a unique forum for knowledge exchange and sharing of best practice in diabetes prevention, education and treatment, helping to foster the collaborations, connections and political breakthroughs that are required to improve the lives of people living with diabetes, help protect those at risk and reduce the impact of diabetes on our societies.
I look forward to welcoming you in Abu Dhabi to help shape the future of diabetes through a strong and united voice.
Dr Shaukat SadikotPresident, International Diabetes Federation
WELCOME TO THE IDF CONGRESS
2017
32
CONGRESS COMMITTEES
Organising Committee
• Monira Al Arouj Kuwait Chair• Abdulrazzaq Al Madani UAE Member• Abdullah Ben Nakhi Kuwait Member• Nam Cho Korea Member• Linong Ji China Member• Banshi Saboo India Member
National Advisory Committee
• Abdulrazzaq Al Madani UAE Chair• Mubarak Hamad Al Shamsi UAE Member• Lindsay Fraser UAE Member• Khalid Al Jaberi UAE Member• Fatheya Al Awadi UAE Member• Juma Al Kaabi UAE Member• Khalifa Al Qubaisi UAE Member• Salem Al Marzouqi UAE Member• Bakhit Al Kathiri UAE Member• Jamal Al Khateri UAE Member• Mzyed Al Otaibi UAE Member• Ateeq Al Mazrouei UAE Member
Programme Committee
• Nam Cho Korea Chair
Welcome to Abu Dhabi
On behalf of the Organising, Programme and National Advisory Committees, we are delighted to welcome you to the IDF Congress 2017 in Abu Dhabi, UAE.
IDF’s biennial congress is the most significant global diabetes event, convening the international diabetes community through its vibrant and diverse scientific programme, satellite symposia, exhibition and global village, showcasing the membership of IDF of
over 230 national associations and societies in 170 countries.
Abu Dhabi, the capital of the United Arab Emirates, a destination where the past is preserved, cherished and respected while the future is meticulously planned and considered, will host a scientific programme comprised of nine streams, introducing new areas such as diabetes and disasters, diabetes in women and children and diabetes in society and culture. Building on the experiences gained from past congresses, IDF 2017 will feature more
e-poster presentations, shorter session formats and overflow capacities in every session hall. All improvements intended to maximise the congress experience for all participants.
The venue’s state of the art facilities, modern infrastructure and top level service will provide the ideal setting for delegates to share the latest scientific advances in the field, learn from each other’s expertise and experience, and develop strategies for national, regional and global efforts to advance diabetes treatment, improve the lives of people with diabetes and prevent the continued rise of the epidemic.
We look forward to welcoming you to an exceptional congress, which we hope will have a lasting legacy for all involved.
Dr Monira Al Arouj Professor Nam Cho Dr Abdulrazzaq Al MadaniChair, Organising Committee Chair, Programme Committee Chair, National Advisory Committee
54
Streams
Basic and Clinical Science • Kyong Soo Park Korea Lead• Raimund Weitgasser Austria Deputy • Young-Bum Kim USA Member• Ahmed Reja Ethiopia Member• Michael Roden Germany Member• Susumu Seino Japan Member• Cees Tack The Netherlands Member
Science of Diabetic Complications • Isaac Sinay Argentina Lead • Kamil Salamah Saudi Arabia Deputy • Larry Distiller South Africa Member• Ramon Gomis Spain Member
Diabetes and Disasters • Nizar Albache Syria Lead• Sidartawan Soegondo Indonesia Deputy • Abdul Basit Pakistan Member• Manuel Vera Gonzalez Cuba Member
Diabetic Foot • Lawrence Harkless USA Lead• Ammar Ibraham Dominican Republic Deputy • Norina Alinta Gavan Romania Member• Crystal Holmes USA Member
Diabetes in Society and Culture • Massimo Massi Benedetti Italy Lead • Predrag Djordjevic Serbia Deputy• Fatheya Al Awadi UAE Member• Edwin Jiménez Costa Rica Member
Diabetes in Women and Children • Hak Chul Jang Korea Lead• Moshe Hod Israel Deputy • Catherine Kim USA Member• Ronald Ma Hong Kong, China Member
Education and Integrated Care • Edwin Fisher USA Lead• Anil Bhoraskar India Deputy • Felix Assah Cameroon Member• Adriana Forti Brazil Member• Zilin Sun China Member
Epidemiology and Public Health • Jaakko Tuomilehto Finland Lead• Soo Lim Korea Deputy • Helen Colhoun United Kingdom Member• Rafael Gabriel Spain Member• Edward Gregg USA Member• Naomi Levitt South Africa Member
Living with Diabetes• Manny Hernandez USA Lead• Renza Scibilia Australia Deputy • Hakeem Adejumo Nigeria Member• Kelly Close USA Member• Mary Shi China Member
KEY DATES
Scientific programme • June 2017 - Fully searchable scientific programme online• October 2017 - Congress app goes live
Abstracts & Grants • 1 February 2017 - Abstract submission
and grant application open• 21 April 2017 - Abstract submission closes• 28 April 2017 - Grant application closes• Mid-July 2017 - Abstract selection notification• Early-August 2017 - Grant application notification
Registration • 2 January 2017 - Online registration opens• 18 August 2017 - Early-rate deadline• 13 November 2017 - Online registration closes
76
CONGRESS-AT-A-GLANCE
Monday 4 Dec Tuesday 5 Dec Wednesday 6 Dec Thursday 7 Dec Friday 8 Dec
08.00
Satellite Symposia
Scientific Sessions
Scientific Sessions
Scientific Sessions
Scientific Sessions
09.30
Exhibition
Exhibition
Exhibition
10.00
Scientific Sessions
Scientific Sessions
Scientific Sessions
Scientific Sessions
11.3011.45 Posters Posters Posters Meet the
Satellite Symposia Satellite Symposia Satellite Symposia Speakers12.45
13.15
Scientific Sessions
Scientific Sessions
Scientific Sessions
Scientific Sessions
14.45
15.15
Scientific Sessions
Scientific Sessions
Scientific Sessions16.00
16.45
17.00
17.30
Satellite Symposia
Satellite Symposia
Satellite Symposia
18.00
Opening19.30
5K@IDF Farewell Evening
WHY ATTEND THE IDF CONGRESS 2017?
Learn • 160 hours of scientific sessions• Over 1000 posters• CME credits to advance your learning
Discover • Cutting-edge science• 9 programme streams• 70 international exhibitors
Connect • 250 speakers• 12 000 delegates• 230 IDF members
98
Stream Lead, Diabetes in Society and CultureDr Massimo Massi Benedetti is former Associate Professor of Endocrinology at the University of Perugia (I), Co-Director of the WHO Collaborating Centre for Quality Development in Diabetes, Scientific Director of the Dasman Diabetes Centre in Kuwait, Former President of IDF Europe and IDF Vice-President. He is also a member and leader of various EU research projects. At
present, he is President and Scientific Director of the Hub for International Health Research-HIRS.
Stream Lead, Diabetes in Women and ChildrenDr Hak Chul Jang works in the Department of Internal Medicine at Seoul National University Bundang Hospital and Seoul National University College of Medicine. Professor Jang’s research focuses on the clinical epidemiological study of gestational diabetes mellitus, the long-term follow-up study of women with gestational diabetes mellitus, insulin resistance and
beta-cell function in high risk population, sarcopenia and sarcopenic obesity and U-healthcare in diabetes care.
Stream Lead, Education and Integrated CareDr Edwin Fisher is a public health professional, noted researcher and clinical psychologist. He also is a former chair of the Department of Health Behaviour at the Gillings School of Global Public Health. Dr Fisher has wide-ranging research interests. He serves as Global Director of Peers for Progress, a program that documents the benefits of peer support in diabetes
management and conducts diverse activities to promote peer support around the world. Over his career, Dr Fisher has led multiple large and
influential research projects. Among the topics he has researched are chronic disease prevention, management and quality of life, asthma, cancer, cardiovascular disease, smoking and weight management.
Stream Lead, Epidemiology and Public HealthProfessor Jaakko Tuomilehto is Professor Emeritus of Public Health, University of Helsinki, Finland, and currently working as the Chief Scientific Officer at Dasman Diabetes Institute in Kuwait. His research interests include the epidemiology and prevention of diabetes. He has contributed to many landmark studies, the Finnish Diabetes Prevention Study and the
WHO DIAMOND study mapping the incidence of childhood-onset type 1 diabetes. He currently serves as the Editor-in-Chief of Primary Care Diabetes. He has contributed to over 1600 peer-reviewed publications and has h-index 159.
Stream Lead, Living with DiabetesMr Manny Hernandez was born in Venezuela and is living in the San Francisco Bay Area and has lived with diabetes since 2002. As an advocate, he co-founded the Diabetes Hands Foundation in 2008 and led the organisation until 2015. Since then he has been a part of the executive team at Livongo Health. Manny believes that nobody living with diabetes should ever feel alone.
PROGRAMME COMMITTEE
Programme ChairProfessor Nam Cho currently resides in the Republic of Korea and is the President-Elect of the International Diabetes Federation. Professor Cho is a world renowned diabetes epidemiologist. He was a medical faculty at North-western University Medical School until he was recruited by the Korean government’s “Korean national brain pool recruitment
project” in 1994. He has published over 200 peer reviewed papers on type 1 diabetes, type 2 diabetes and gestational diabetes. Professor Cho has served as Chairman of the Department of Preventive Medicine at Ajou University School of Medicine and is a Director of Clinical Epidemiology at the university’s hospital. Since 2000, he has served as the president of a humanitarian medical NGO, which provides medical services to under-developed countries. In 2015 he received an insignia from the King of Cambodia for 15 years of unselfish humanitarian medical services and the construction of a National Diabetes Centre.
Stream Lead, Basic and Clinical ScienceProfessor Kyong Soo Park is a Professor of Internal Medicine in the Division of Endocrinology and Metabolism at Seoul National University College of Medicine. Professor Park’s research focuses on the genetics of type 2 diabetes mellitus and the mechanism of insulin resistance in skeletal muscle.
Stream Lead, Science of Diabetic ComplicationsDr Isaac Sinay is an advisor at the diabetes unit at the Cardiovascular Institute of Buenos Aires in Buenos Aires, Argentina. He is a member and former president of the “Sociedad Argentina de Diabetes” and of the “Sociedad Argentina de Endocrinologia y Metabolismo”. He was a principal investigator for more than 20 clinical trials (phases II, III and IV) and has authored
more than 50 scientific publications in the field of diabetes and endocrinology.
Stream Lead, Diabetes and DisastersDr Nizar Al Bache from Syria is the Chair of the Middle East and North Africa (MENA) Region of the International Diabetes Federation for 2016-17. He has over 30 years of experience in the management of type 1 and type 2 diabetes and endocrine diseases. Dr Al Bache was a medical doctor at the Aleppo University Hospital and in a private endocrine and diabetes centre in
Syria from 1985 to 2012. He has also been Assistant Professor teaching diabetes and endocrine diseases at the Faculty of Medicine, Aleppo University.
Stream Lead, Diabetic FootDr Lawrence Harkless is Founding Dean of the College of Podiatric Medicine and Professor of Podiatric Medicine, Surgery and Biomechanics at the Western University of Health Sciences. He has educated thousands of students, residents, physicians and healthcare providers about the complexities of diabetic foot complications and the importance of preventative foot care for
people with diabetes as well as operating his own private practice.
1110
1312
LEARNING OBJECTIVES
Basic and Clinical Science
Description This stream deals with recent progress in both basic and clinical diabetes research and also presents the latest advances in clinical practice and their application in diabetes care.
Learning ObjectivesAfter attending a session in the Basic and Clinical Science stream the participant will be able to:• Understand some of the latest advances in basic research related to
the pathogenesis and treatment of diabetes mellitus• Understand recent advances in clinical research as well as clinical
practice in the real world• Take the evidence and underpinnings of current clinical research
and be able to apply them to the interpretation of clinical data• Apply the most up-to-date evidence-based research to clinical
practice
Science of Diabetic Complications
DescriptionThis stream deals with the basic and clinical science of diabetic complications, the latest research into these complications and up-to-date prevention politics and treatments.
Learning ObjectivesAfter attending a session in the Diabetic Complications stream the participant will be able to:• Understand the epidemiology, physiopathology, diagnosis,
prevention and treatment of the complication developed in the session
• Decide how to individualise the diagnostic, prevention and treatment tools in the setting where he/she operates as healthcare practitioner
• Define the appropriate moment to refer the patient to a level of greater complexity
Diabetes and Disasters
DescriptionThis new stream will present experiences with dealing with diabetes and disasters, both natural and man-made, and provide practical information on how to be prepared to help people with diabetes before and during disasters.
Learning ObjectivesAfter attending a session in the Diabetes and Disasters stream the participant will be able to:• Evaluate the possible risks for people with diabetes and healthcare
providers during disasters• Plan practical steps to help people with diabetes before and during
disasters• Cooperate and coordinate with NGOs and other organisations
working in the humanitarian field
Diabetic Foot
DescriptionThis stream deals with the basic and clinical science of diabetic foot as well as the epidemiology and public health challenges presented by the condition. It also focuses on education and care needed for management and prevention of diabetic foot.
Learning ObjectivesAfter attending a session in the Diabetic Foot stream the participant will be able to:• Identify the importance of prevention of diabetic foot and to be
able to detect the risk factors for it• Understand the latest innovations in diabetic foot treatment• Better understand the impact of diabetic foot problems on patients,
their families and on the health system• Use available resources to improve the outcome of patients with
diabetic foot• Correctly plan the establishment of diabetic foot centres
Diabetes in Society and Culture
DescriptionThis stream will deal with all aspects of the diabetes epidemic in different societies and how these societies can help with prevention and management.
Learning ObjectivesAfter attending a session in the Diabetes in Society and Culture stream the participant will be able to:• Better understand the complexity of real life interventions for
primary and secondary prevention and chronic care management of diabetes
• Define how environmental and cultural factors influence the management of diabetes and the life of people with diabetes
• Identify roles and responsibilities for improving the life of people with diabetes according to opportunities and barriers present in different societies and cultures
Diabetes in Women and Children
DescriptionThis stream will focus on all aspects of hyperglycaemia in pregnancy including gestational diabetes and pregnancy in people with diabetes. It will deal with the long-term effects on mother and child regarding metabolic and cardiovascular disease. It will also deal with diabetes in children, from type 1 to the emerging issue of type 2 diabetes in children.
Learning ObjectivesAfter attending a session in the Diabetes in Women and Children stream the participant will be able to:• Understand that hyperglycaemia in pregnancy (HIP) is one of
the most common medical conditions women encounter during pregnancy
• Understand that HIP is associated with a higher incidence of maternal mortality, maternal morbidity, perinatal and neonatal morbidity and long-term consequences for both mother and child
• Understand that pregnancy offers a window of opportunity to establish services, improve health and prevent intergenerational transmission of non-communicable diseases
• Take the evidence and underpinnings of current clinical research and be able to apply them to the interpretation of clinical data
• Apply the advanced evidence-based research regarding HIP to clinical practice
Education and Integrated Care
DescriptionThis stream includes the latest developments in diabetes education and care and their application and integration through healthcare professionals, families and communities.
Learning ObjectivesAfter attending a session in the Education and Integrated Care stream the participant will be able to:• Describe how people with diabetes effectively manage their own
care and the role healthcare professionals play in supporting this• Develop improved training for multidisciplinary healthcare providers• Use a variety of tools and intervention approaches that enhance
patients’ ability to manage their diabetes and their health in general
• Work with patients, their families, and communities to improve understanding of diabetes, its prevention and care, and the quality of life of those with diabetes
• Address a variety of specific challenges in diabetes prevention and care worldwide
1514
Epidemiology and Public Health
Description This stream deals with the latest trends in diabetes and its complications, the public health challenges being faced and how to prevent them.
Learning ObjectivesAfter attending a session in the Epidemiology and Public Health stream the participant will be able to:• Recognise the crucial importance of continuing to work on
prevention and how to overcome modern challenges to metabolic health
• Describe how current epidemiological data can be used to help shape future policy and healthcare implementation
• Translate successful strategies from projects presented into future prevention programmes
Living with Diabetes
DescriptionThis stream provides the participant with the perspective of the person with diabetes and how the person with diabetes can have an impact on the diabetes epidemic.
Learning ObjectivesAfter attending a session in the Living with Diabetes stream the participant will be able to:• Recognise the multiple aspects of living the best life possible with
diabetes• Understand some of the day-to-day challenges faced by people
with diabetes• Identify technologies with potential for positive impact on diabetes
management • Be a powerful enabler of positive self-care.
PROGRAMME PREVIEW
Programme Sessions
Debates Two opposing teams will defend and refute current topics to do with diabetes.
Meet-the-Experts Participants are given the opportunity to interact with one or more experts on a specific topic.
Open Forums Participants are given the chance to discuss a specific topic with a panel of experts.
Symposia Symposia will showcase the latest findings in diabetes research and current issues in therapy and education.
Teaching Lectures Recognised experts will give educational lectures on specific topics. This format will combine a lecture with a question and answer section.
Workshops Specific topics will be discussed accompanied by practical demonstrations, problem-solving or hands-on training sessions.
Oral Poster Presentations Poster authors discuss their findings with an audience during a dedicated session.
Poster DisplaysA collection of selected abstracts will be displayed as posters.
16 17
PROGRAMME TOPIC OVERVIEW
Basic and Clinical Science
Type 1 diabetes• The environmental impact that interacts with the genetic
predisposition for type 1 diabetes• Cell replacement for type 1 diabetes• Arresting autoimmune disease in type 1 diabetes: towards antigen-
specific interventions• Latent Autoimmune Diabetes in Adults (LADA)
Basic research• Comparative study of genetics risks factors of type 2 diabetes
mellitus and related traits in African, American, Asian and European populations
• Precision medicine: the many ways in which genomics might, or might not, optimise diabetes prevention and treatment
• Is epigenetics the missing link between the environment, our genome and type 2 diabetes and complications?
• The role of the brain in metabolic regulation• Metabolic signals that control glucose homeostasis• Novel regulators of insulin resistance• Mitochondria and energy metabolism in obesity and diabetes: a
new therapeutic target• Interactions between gut microbes: bacteria, metabolites and
regulation of glucose homeostasis• Lessons learned on diabetes pathogenesis based on human
pancreas/islets• Pathophysiology of diabetes in different populations: basic to
clinical perspectives• Glucagon in physiology and pathophysiology
Clinical research and management• Obesity management for the treatment of type 2 diabetes: low-
calorie and very low-calorie diet, weight loss medications, bariatric/metabolic surgery - which treatment for which patient?
• Incretins and their pleitropic actions
• SGLT-2 inhibitors should be the first-line therapy for type 2 diabetes• Innovative insulin delivery and insulin clearance• Synergism through combination: which drugs should be used
together?• New pharmacologic approaches to the treatments of type 2 diabetes• What do clinicians need to know about hypoglycaemia in clinical
practice?• Clinical implications of emerging biomarkers in type 2 diabetes• Information and communications technologies in diabetes
management• Should there be an entirely new way to classify diabetes?• Diabetes and cancer• Diabetes in elderly
Cardiovascular outcome trials of glucose lowering agents
NAFLD in diabetes and the metabolic syndrome: clinical guidelines and practical recommendations
Post transplantation diabetes and its management
Science of Diabetic Complications
Vascular disease• Non-severe hypo and macrovascular outcomes: does it damage?• Endothelial damage attributable to hyperglycemia: is it similar in
micro and macrovasculature?• Prediabetes and macrovascular impact• Gestational diabetes and micro and microvascular impact
Nephropathy• Diabetic nephropathy: from the beginning• Biomarkers in the early diagnosis of diabetic nephropathy• Combining ACEI with ARBs in early diabetic nephropathy: what is
the verdict?
Neuropathy• Autonomic neuropathy
Retinopathy• Challenges in diabetic retinopathy: what to do in low and middle
income countries?
Cardiovascular disease• Impact of antihyperglicemic therapy in cardiovascular disease: past,
present, future and actual translation into clinical practice• Non-invasive methods for detecting cardiovascular diseases in
patients with diabetes• Diagnosis and treatment of cardiovascular diseases and
microvascular impact in women with diabetes: first world and low and middle income countries - are there differences?
Other complications• Forgotten complications of diabetes• Non-alcoholic fatty liver disease• Diabetes and cognitive decline• Euglycemic ketoacidosis
Diabetes and Disasters
Diabetes and natural disasters
Diabetes and man-made disasters: conflicts and war
Preparing for disasters
The role of humanitarian organisations
Lessons from the past
Diabetic Foot
Prevention• Prevention: how to mobilise patient organisations• Organisations for educating patients
Health workforce• Educating health care providers in primary care • Certification of physicians and community health workers• Certification of medical centres providing outpatient and inpatient care
Treatment• Footwear for people with diabetes and people with symptoms of
diabetic foot• What next after amputation? Prostheses in different settings• Infection • Peripheral arterial disease in people with diabetes
Research into diabetic foot
Diabetes in Society and Culture
Diabetes and sustainable development• Health policies in all policies for primary and secondary prevention
of diabetes• Prevention based on science of improvement• Real-life evidence in diabetes• Diabetes registries and big data• Diabetes and public-private partnerships
Disenfranchised and vulnerable populations• Impact of income, education, gender, age, social class on diabetes• Diabetes in migrants (not refugees)• Insulin for Life• Life For A Child• The role of service organisations and charities
1918
Advocacy• Ethics and diabetes• Discrimination• Integration of people with diabetes in the society: the impact of
cultural backgrounds
Health anthropology• Early diagnosis of type 1 diabetes and prevention of diabetic
ketoacidosis according to different societies and cultures• Diabetes foot care according to different societies and cultures• Food and beliefs• Traditional healers• Diabetes and Ramadan
Social and economic factors influencing epigenetics
Camps
Diabetes in Women and Children
Diabetes in women• Reproduction issues in women with diabetes: infertility,
contraception and menopause
Diabetes during pregnancy• Detection and diagnosis of the abnormal carbohydrate metabolism
during pregnancy• Management of diabetic pregnancy; medical nutritional therapy
and pharmacological therapy during pregnancy• Prevention of gestational diabetes in high risk individuals
Diabetes in children• Management of children and adolescents with type 1 or type 2
diabetes
Prediction and prevention of type 2 diabetes and/or cadiometabolic syndrome in mothers and their offspring
Education and Integrated Care
Intervention and patient education strategies and challenges• Low carbohydrate diet• Preventing hospitalisations
Professional education and training• Including education on comorbidities
Broadening and integrating care• Community health workers, peer support, health coaches, etc.• Community approaches to care• Integration of primary and specialty care with community resources
“High tech” and information technology, and related innovations• Social media• Big data analyses and applications• Digital health, including mobile and eHealth applications
Interventions for special populations• Immigrant groups• Indigenous groups• Refugees• Stigmatised ethnic minorities• Groups stigmatised by gender identity• Low-income groups
Integrating medical advances into routine care and practice• Multi-pharmacy and the role of the pharmacist
Quality of life and psychosocial well being
National examples of progressive and integrated care
Prevention• Emphasis on primary prevention
Community and policy• Inter-sectoral policies
National diabetes plans
Epidemiology and Public Health
Epidemiological studies• Epidemiology: observation studies• Current status of risk factor studies • Global increase in type 1 diabetes: new estimates• Type 2 diabetes: MENA observational study
Diabetes prevention• Prevention of gestational diabetes and complications• Prevention trials• Prevention in the workplace and productivity
Healthcare • Reimbursement of prevention services• Cost issues relating to complications• Criteria to start pharmacotherapy
Type 1 diabetes in young adults
Risk factors for gestational diabetes and type 2 diabetes
Complications• Retinopathy, cardiovascular disease and dementia
Efficacy trials
Genetics• Gene-lifestyle interactions• Genetic risk scores
Living with Diabetes
Peer-to-peer support and education• The perspective of the person with diabetes• Face to face vs. online peer support
Hypoglycemia from the point of view of the person with diabetes• How does hypoglycemia feel?• Fear and impact on quality of life
Children and young adults with diabetes• Transition from pediatric to adult care• Parental acceptance of diagnosis
Diabetes advocacy: nothing about us without us• The symbiosis between diabetes organisations and people with
diabetes• Global examples (Africa, South Asia, USA)
Diabetes technology: digital health and mobile tools• Apps and tools: a landscape overview• Culturally appropriate digital tools• We’re not waiting vs. why we are waiting
Thriving with diabetes• A long happy life with diabetes• Balancing diabetes: knowledge and temptations, fatigue and
motivation
The stigma of diabetes• Language matters: when speaking to and about people with diabetes• Appropriate interventions
Diabetes complications from the point of view of the person with diabetes• The emotional fallout of a complication diagnosis
Diabetes and mental health• Distress• Diabulimia
2120
2322
CALL FOR ABSTRACTS
Abstract Submission
The IDF Congress 2017 welcomes original abstracts on subjects relevant to the following 9 streams:• Basic and Clinical Science • Science of Diabetic Complications• Diabetes and Disasters• Diabetic Foot• Diabetes in Society and Culture• Diabetes in Women and Children• Education and Integrated Care• Epidemiology and Public Health• Living with Diabetes
GuidelinesOnline abstract submission opens on 1 February and closes on 21 April 2017.
• Submission mode: Abstract submission is only possible online at www.idf.org/congress. Abstracts submitted by post, fax or email will NOT be accepted. The online abstract submission module will NOT be available after 21 April 2017.
• IDF congress profile: In order to submit an abstract, a congress profile must be created giving access to the online abstract submission module. The submitting author must ensure accurate contact details are entered. One or more abstracts can be submitted by logging into this congress profile.
• Submitting author / presenting author: If the submitting author is not also the presenting author, the submitting author is responsible for informing the presenting author of all communications received regarding the abstract.
• Presenting author registration: The presenting author must be registered by 15 September 2017. If the presenting author is not registered by 15 September 2017 their abstract will be REMOVED from the programme. To benefit from the early registration rate, the presenting author must register by 18 August 2017, after that date the standard rate will apply.
• Number of submissions: There can only be ONE presenting
author per abstract. The same abstract CANNOT be submitted multiple times by different submitting authors or by listing different presenting authors. An unlimited number of abstracts can be submitted by an author.
• Language: All abstracts must be submitted in English. Should English not be your first language, you may wish to have your abstract examined by a native English speaker prior to submission.
• Accuracy of content: Submitted abstracts may be edited online up to the abstract submission deadline of 21 April 2017. Abstracts CANNOT be edited or revised in any way after the deadline. All accepted abstracts will be published as submitted by the authors. The responsibility for the submission of an accurate and precise abstract lies solely with the authors.
• Originality of abstracts: Work published elsewhere before 4 December 2017 should NOT be submitted to the IDF Congress 2017. However, previously published work can be resubmitted provided there are new methods and/or findings.
• Disclosure of interests: Any financial relationships with commercial entities related to the authors or products and processes described in the work must be correctly disclosed.
• Regulatory approval: The submitting author confirms that local regulatory approval has been obtained as required by local laws.
• Author consent: The submitting author declares all authors have read and approved the submitted work.
• Copyright transfer: Authors must attest that their submitted work does not infringe any copyright legislation. Copyright for the publication of abstracts is automatically transferred to the International Diabetes Federation upon submission and acceptance of the regulations within the online submission module. For rejected abstracts, the copyright reverts back to the authors.
Instructions• Category & stream: There are various categories that have
been defined for the abstract programme within the nine streams. Ensure that you select the MOST relevant stream and then place it in the category which BEST describes the content
of your abstract. Categories are used for reviewing and indexing purposes.
• Abstract title: The title is limited to 120 characters including spaces and should be brief and relevant. Special characters should NOT be used in your title but spelt out instead (e.g. α should be written as alpha, β as beta). Only use standard abbreviations and generic drug names in the title.
• Authors: Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.
• Abstract body:• The abstract structure is laid out under the headings
Background, Aims, Method, Results and Discussion. • Font size and style will be automatically configured by the
system.• Tables will be accepted in the submission field and count
towards the word limit. The word deduction for tables is not fixed and will be generated by the word count shown below the submission field. Graphs, figures and photographs are NOT allowed.
• The length of the abstract is limited to 700 words. Only the abstract body and any inserted tables count towards this word limit. The word count displayed beneath the submission field is final and indisputable.
• Only commonly accepted abbreviations should be used. Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage.
• Only approved and generic (non-proprietary) drug names should be used.
• Do NOT enter the title, authors, or grant information into the abstract body submission field but include any references at the end of the abstract.
Selection and notification process• Selection: All submitted abstracts undergo a peer-review
process by an international panel of reviewers. Accepted abstracts are selected for oral poster presentation or poster display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.
• Notification: Notice of acceptance or rejection of submitted abstracts will be sent to the submitting authors by mid-July 2017. It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of the abstract.
• Author Registration: Presenting authors of accepted abstracts MUST register for the congress by 15 September 2017. If the entire registration fee is not paid by the deadline, the abstract will be automatically withdrawn and will NOT be presented or published. To benefit from the early registration rate, authors must register by 18 August 2017.
• Presenting author changes: Changes to the presenting author for an abstract need to be requested using the appropriate form which can be found on the congress website www.idf.org/congress.
Late-Breaking Abstract Policy
Please note that the IDF Congress 2017 will not be accepting late-breaking abstracts. All abstracts must be submitted during the regular submission period starting on 1 February and ending on 21 April 2017.
2524
Abstract Categories
• Bariatric surgery• Blood pressure• Care delivery• Cognition, psychology and behaviour• Comorbidities• Complications• Complications - cardiovascular disease• Complications - eye• Complications - foot• Complications - kidney• Complications - nerve• Complementary medicine• Diabetes advocacy• Diabetes and infections• Diabetes and the brain• Diabetes organisations• Diabetes education• Diabetes epidemiology• Diabetes in childhood and adolescence• Diabetes in Indigenous groups• Diabetes in rural areas• Diabetes in the elderly and vulnerable populations• Diabetes management• Diagnosis and classification• Discrimination and diabetes• Education and development for healthcare professionals• Engagement of people with diabetes• Environment and lifestyles• Epigenetics• Genetics of diabetes• Glucagon• Guidelines, clinical care• Health services research• Health workforce• Healthcare financing• Hypoglycaemia• In utero environment• Incretin physiology and pathophysiology
• Incretin therapies• Inflammation• Insulin action• Insulin secretion, beta-cell function• Insulin therapy and devices• Islets - beta-cell biology• Lipids and lipoproteins• Living with diabetes• Microbial flora• Nutrition and diet• Obesity• Oral glucose-lowering therapies• Physical activity• Pregnancy and gestational diabetes• Primary and secondary prevention• Rights and responsibilities of people with diabetes• Screening and risk stratification• Stem cell therapy• Telecommunication, internet and social media• Transplantation - islet and pancreas• Type 1 diabetes• Type 2 diabetes
IDF Congress Grant
The IDF congress grant aims to provide 100 people from around the world with the opportunity to attend the congress and present their work.Grant applicants should:• Be no more than 35 years of age at the time of the congress• Submit an abstract to be approved by the Programme Committee• Fill in the online grant application form Accepted grantees are offered free registration, up to 4 congress nights’ accommodation and an economy return flight to Abu Dhabi, UAE. Online grant submission opens on 1 February and closes on 28 April 2017.
Continuing Medical Education (CME)
Applications for Continuing Medical Education (CME) accreditation for physicians and other healthcare professionals will be presented to the national accreditation body and the European Accreditation Council for Continuing Medical Education (EACCME). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). It is expected that the IDF Congress 2017 will be accredited with between 20 and 22 hours of CME credits. CME certificates will be available to print in the congress centre and online as of Thursday 7 December 2017.
2726
REGISTRATION
Individual Registration
• Participants are required to register online at www.idf.org/congress as of January 2017. A valid email address will be required.
• Registration and corresponding payment should be received by 13 November 2017.• After that date, the online registration system will no longer be available and registration will only be
possible on site. • Registration at the on-site rate will be possible during the congress (4 December - 8 December 2017). Day
rates will also be available on site.
Registration opening hours
Days HoursMonday 4 December 07.00 – 18.00Tuesday 5 - Thursday 7 December 07.00 – 18.00Friday 8 December 07.00 – 11.00
Registration rate structure (all indicated amounts are in EUR)
Category Early rateUntil 18 Aug 2017
Standard rateFrom 19 Aug 2017
Onsite rate4-8 Dec 2017
Day rate 4-8 Dec 2017
Regular rate 550 880 990 330Reduced rate (1) 400 600 700 330Student (2) 110 110 110 110Low-income economies (3) 220 330 440 165
(1) This reduced rate is available for healthcare professionals other than medical doctors, and for medical doctors 35 years or younger at the time of the congress. Applicants for this rate must send a copy of their ID/passport (for young doctors) and professional ID for healthcare professional to [email protected].
(2) This reduced rate is available for participants who are students at the time of the congress. This rate is not applicable to persons holding a post-doctorate degree. Applicants for the student rate must send their valid student ID to [email protected].
(3) This reduced rate is available for participants who are citizens AND residents of a low-income country as per World Bank classification.
Group Registration
• Group registration is available for groups of at least 10 participants. One contact person should coordinate with the Congress Secretariat.• The group rate is at the regular rate per person. New group rate discounts are now available. • All registration information will be sent to the group contact person, who will then be responsible for distribution to the group.• A special module for group registration is accessible online at www.idf.org/congress.• The group contact person will receive detailed instructions on how to collect the group’s registration badges.
Payment
Payment should preferably be made by credit card (Eurocard/Mastercard, VISA or American Express). Please indicate the card owner’s name (as shown on the card) and the expiry date.Payments can also be done by direct bank transfer without charges to the beneficiary:• Beneficiary name: IDF• Account name: IDF Congress• Account number / IBAN: BE67 6451 4103 3587• Swift code / Routing: BIC JVBABE 22• Bank name: Bank: J. Van Breda & Co• Bank address: Vlaanderenstraat 53, 9000 Gent, Belgium.
The name and address of the participant should be clearly stated on the bank transfer.Please bear in mind that an international bank transfer can take up to 10 days to reach our account.If payment is not received by the corresponding deadline (early or standard registration), the subsequent rate will automatically apply.
Name change/cancellation for individual registrantsAll name changes and cancellation requests must be done in writing by email. No changes or cancellations will be accepted by telephone. A name change for a confirmed registration will be subject to an administrative fee of 50 EUR per participant.Cancellation of a confirmed registration will be subject to an administrative fee of 50 EUR per participant. Please note that if you cancel after 13 November 2017, no refund will be possible.
RefundsPlease note that any applicable refund will be reimbursed after the congress.
2928
ACCOMMODATION, TRAVEL AND VISA
International Conference Services (ICS) is the official housing bureau for the IDF Congress 2017 and will offer assistance with the coordination of housing requests. A wide variety of hotels have been secured in the heart of Abu Dhabi and within walking distance to the congress venue.
Bookings
All sponsors, exhibitors and delegates are encouraged to book at the official IDF congress 2017 hotels to benefit from special rates.
IDF Congress Housing Bureau Contact:Tel: +1 720 325 2944Fax: +1 604 681 2153Email: [email protected] Groups bookings (10 or more): [email protected] Tel: +1 236 521 0014
Accommodation
3130
Hotels Distance from ADNEC Star RatingSingle Occupancy Rate
(Incl. Breakfast & HS Internet)
Zone 1 – Corniche Area
Crowne Plaza Hotel 20 minute drive 5 AED 740
Hala Arjaan Hotel 20 minute drive 4 TBC
Hilton International Hotel Abu Dhabi 25 minute drive 5 TBC
Khalidiya Palace Rayhaan 20 minute drive 5 TBC
Le Royal Meridien Abu Dhabi 20 minute drive 5 AED 650
Corniche Hotel 20 minute drive 5 AED 650
Ramada Hotel 20 minute drive 4 AED 480
Sheraton Abu Dhabi Hotel 20 minute drive 5 AED 740
Sofitel Abu Dhabi Corniche 20 minute drive 5 AED 917
Southern Sun Hotel 20 minute drive 4 AED 860
St.Regis Abu Dhabi Hotel 20 minute drive 5 AED 960
Zone 2 – Metropolitan City Area
Beach Rotana 25 minute drive 5 TBC
Centro Al Manhal 15 minute drive 3 TBC
City Seasons Al Hamra Hotel 20 minute drive 4 TBC
Courtyard By Marriot, World Trade Centre 20 minute drive 4 AED 570
Dusit Thani Abu Dhabi Hotel & Apartments 15 minute drive 5 AED 375
Grand Mercure Majilis 20 minute drive 5 TBC
Holiday Inn Abu Dhabi Downtown 20 minute drive 4 TBC
Marriott Downtown 20 minute drive 4 AED 641
Royal Rose Hotel 20 minute drive 5 AED 550
Zone 3 – ADNEC Area
Aloft Abu Dhabi Hotel 3 minute walk 4 AED 615
Centro Capital Centre 3 minute walk 3 AED 911
Hyatt Capital Gate, Abu Dhabi Hotel 5 minute walk 5 AED1,413
Premier Inn Abu Dhabi Capital Centre 5 minute walk 3 AED 542
Zone 4 – Zayed Sports City Area
Hilton Capital Grand Abu Dhabi 5 minute drive 5 TBC
Hotels Distance from ADNEC Star RatingSingle Occupancy Rate
(Incl. Breakfast & HS Internet)
Zone 5 – Khor Al Maqta Area
Armed Forces Officer's Club & Hotel 10 minute drive 5 AED 511
Fairmont Bab Al Bahr Hotel 15 minute drive 5 AED1,200
Ibis Gate Hotel 10 minute drive 3 TBC
Novotel Abu Dhabi Gate Hotel 10 minute drive 4 TBC
Shangri-La Hotel - Qaryat Al Beri 15 minute drive 5 AED 1,155
The Ritz Carlton Abu Dhabi 10 minute drive 5 TBC
Traders Hotel - Qaryat Al Beri 12 minute drive 4 AED 550
Zone 6 – Eastern Corniche Area
Holiday Inn Abu Dhabi 7 minute drive 4 AED 911
Novotel Abu Dhabi Al Bustan 7 minute drive 4 TBC
Park Rotana Hotel 9 minute drive 5 TBC
Zone 7 – Al Bateen Area
Bab Al Qasr 18 minute drive 5 AED 900
Grand Hyatt 30 minute walk 5 AED 790
Intercontinental Hotel Abu Dhabi 20 minute drive 5 TBC
Jumeirah at Etihad Towers 20 minute drive 5 TBC
Zone 8 – Al Zahiyah
Le Meridien Abu Dhabi Hotel 25 minute drive 4 AED 613
Zone 12 – Yas Island
Centro Yas Island 25 minute drive 3 TBC
Crowne Plaza Hotel Yas Island 25 minute drive 4 TBC
Park Inn Yas Island Hotel 25 minute drive 3 AED 660
Radisson Blu Hotel Yas Island 25 minute drive 4 AED 760
Yas Island Rotana 25 minute drive 4 TBC
Zone 13 – Khalifa City
Premier Inn Hotel Abu Dhabi International Airport 25 minute drive 3 TBC
The Westin Abu Dhabi 20 minute drive 5 AED 586
• AED = United Arab Emirate Dirham • TBC = rates still to be confirmed• All rates are subject to applicable taxes and fees: currently at 20% (10% service charge fee, 6% tourism fee, 4% municipality fee)
plus an additional 15 AED per room per night• All Abu Dhabi hotels require valid photo ID upon check-in (Passport, GCC ID, UAE Drivers License or Emirates ID accepted) 3332
Travel
Esser Travel is the official travel agency for the IDF Congress 2017 and will offer assistance with the coordination of travel requests. IDF Congress Travel Agency Contact:T: + 30 21 09632404F: +30 21 09632589Email: [email protected]
Visa
Please see the following information to check if you can obtain a visa on arrival or if you require a prearranged visa to enter the United Arab Emirates.
Visa on Arrival
Citizens of eligible countries/regions are allowed to enter the UAE without a visa prior to arrival:• Passport should be valid for a minimum period of 6 months • Type of Visa: 30 days Tourist visa• Duration of stay: 30 Days including the entry and the departure
days • Number of entries: Only single entry is permitted • An eye scan will be taken at the immigration desk in the airport• Fee: Free of charge• Only normal passports can be used for visa applications (i.e. no
Diplomatic Passports)
Countries Eligible for Visa on Arrival
Andorra, Australia, Austria, Belgium, Brunei, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Italy, Japan, Latvia, Liechtenstein, Lithuania, Luxembourg, Malaysia, Malta, Monaco, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, San Marino, Seychelles, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, United Kingdom, United States of America, Vatican City. *GCC citizens do not need a visa to enter the UAE.
Other Countries - Prearranged Visa
Nationals of countries not included in the Visa on Arrival list will require a prearranged visa to enter the United Arab Emirates.
How to Start an Application
The easiest way to obtain a UAE Visa is to apply online at www.ttsuaevisas.com/idf2017
• Fill out a simple, self-explanatory application form • Keep scanned copies of all the required documents ready • Upload the documents as explained • Pay the corresponding visa fee online through the secure link
A confirmation e-mail will be sent to you when your application has been received. The progress of your application can be checked online.After communication from UAE Immigration, an email will be sent to you with the corresponding decision. Successful applicants will then receive their visas by email. After receiving your visa, you must print it out and carry it with you for boarding the airplaneAlternatively, you can apply for a visa through your nearest UAE embassy.
Notes:
• Passport should be valid for a minimum period of 6 months • Type of Visa: 30 days Tourist visa• Entry into UAE: Within 60 days from and including the visa issuance
day • Duration of stay: 30 Days including the entry and the departure days • Number of entries: Only single entry is permitted • An eye scan will be taken at the Immigration desk in the airport• Fee: AED370 / US$100• Cancellation Charge: AED150 / US$41 per visa• Only normal passports can be used for visa applications (i.e. no
Diplomatic Passports)
Visa Application Processing Times
Please ensure that you give yourself enough time for your visa application to be approved.If the online application link mentioned above is used, then the processing time for an application is typically 3-5 UAE working days (Sunday to Thursday).
Whether an application is approved or not is at the sole discretion of the UAE Immigration Department and it is no other party’s responsibility if the visa is declined. Fees paid in regards to approved or declined applications cannot be refunded.
Issuance of a visa or approval on the visa application does not in any way guarantee the guest the right to enter UAE. The entry is at the sole discretion of the immigration officer at the airport.
3534
CONTACT
All enquiries and correspondence in relation to the congress should be directed to:
International Diabetes Federation Chaussée de La Hulpe 166 B- 1170 Brussels Belgium T: +32 2 543 16 31 F: +32 2 403 08 30 www.idf.org/congress
General [email protected]
Industry [email protected] T: +32 2 543 16 33
Programme and [email protected]
[email protected] T: [+1] 720-325-2944.Group accommodation (10 rooms or more): [email protected] T: [+1] 236 521 0014.
[email protected]: + 30 21 09632404
Join the conversation!Find us on Facebook & Twitter www.facebook.com/intdiabetesfed @IntDiabetesFed #IDF2017
IDF 2017: A HEALTHY CONGRESS
Let’s turn our words into action and make this congress the healthiest yet!
The 5K@IDF
Join us on Wednesday 6 December for the 5K@IDF! Help raise awareness about the importance of a healthy lifestyle in preventing type 2 diabetes and managing all types of diabetes.Participation is free for all. See www.idf.org/congress for more information.
Walk the talk
Forget about the elevators and escalators and take a step for diabetes. Your body will appreciate it!Benefit from coffee & lunch breaks and walk the poster area or enjoy the e-poster presentations, standing ovations welcome!
Food for thought
A varied diet is a cornerstone of health. A choice of healthy meals and snacks will be available at reasonable prices from the food outlets throughout the congress venue.
Move those muscles
Increase your activity by taking part in organised fitness ball exercise sessions throughout the day in the exhibition hall. If you miss a session, feel free to use the area at any time to stretch and work those muscles!
3736
SANOFI FOCUSED ON PATIENTS’ NEEDSSanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to making a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
More information on www.sanofi.com
Sans titre-1 1 15/07/2016 17:10:39
